Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad spectrum of liver conditions that ranges from simple steatosis to hepatic steatosis, fibrosis, and cirrhosis. It is currently the most common chronic liver disease worldwide and is expected to become the leading cause of liver failure and liver transplantation in Europe in the coming years. Furthermore, MASLD is a multisystemic disease whose main cause of morbidity and mortality is cardiovascular disease. Therefore, it has broad social and economic implications, representing a major challenge for global public health. This update summarizes current relevant aspects on the pathogenesis, natural history, and management of MASLD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Medicine - Programa de Formación Médica Continuada acreditado
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
